Parameter |
Treatment |
Treatment |
Treatment |
Treatment |
Stepping test - acute doxycycline (Fig. 1-C)
|
F (4, 43) = 6.51
P < 0.001
|
F (4, 43) = 6.51
P < 0.001
|
F (4, 43) = 6.51
P < 0.001
|
F (4, 43) = 6.51
P < 0.001
|
Time of immobility in the open field - acute doxycycline (Fig.
1-D)
|
F (4, 43) = 11.92
P < 0.0001
|
F (4, 43) = 11.92
P < 0.0001
|
F (4, 43) = 11.92
P < 0.0001
|
F (4, 43) = 11.92
P < 0.0001
|
Distance travelled in the open field - acute doxycycline (Supplementary
table 1)
|
F (4, 43) = 39.02
P < 0.0001
|
F (4, 43) = 39.02
P < 0.0001
|
F (4, 43) = 39.02
P < 0.0001
|
F (4, 43) = 39.02
P < 0.0001
|
Time of immobility in the open field - acute COL-3 (Supplementary table
1)
|
F (1, 16) = 17.278
P < 0.001
|
F (1, 16) = 17.278
P < 0.001
|
F (1, 16) = 17.278
P < 0.001
|
F (1, 16) = 17.278
P < 0.001
|
Distance travelled in the open field – acute COL-3 (Supplementary table
1)
|
F (1, 18) = 18.32
P < 0.001
|
F (1, 18) = 18.32
P < 0.001
|
F (1, 18) = 18.32
P < 0.001
|
F (1, 18) = 18.32
P < 0.001
|
ROS - acute doxycycline
(Fig. 3-G)
|
F (2, 15) = 50.46
P < 0.0001
|
F (2, 15) = 50.46
P < 0.0001
|
F (2, 15) = 50.46
P < 0.0001
|
F (2, 15) = 50.46
P < 0.0001
|
Gelatinolytic activity - acute doxycycline (Fig. 3-I)
|
F (2, 16) = 153.4
P < 0.0001
|
F (2, 16) = 153.4
P < 0.0001
|
F (2, 16) = 153.4
P < 0.0001
|
F (2, 16) = 153.4
P < 0.0001
|
MMP-3 - acute doxycycline (Fig. 3-K)
|
F (2, 16) = 584.0
P < 0.0001
|
F (2, 16) = 584.0
P < 0.0001
|
F (2, 16) = 584.0
P < 0.0001
|
F (2, 16) = 584.0
P < 0.0001
|
ROS - chronic doxycycline
(Fig. 4-I)
|
F (2, 14) = 611.7
P < 0.0001
|
F (2, 14) = 611.7
P < 0.0001
|
F (2, 14) = 611.7
P < 0.0001
|
F (2, 14) = 611.7
P < 0.0001
|
Gelatinolytic activity - chronic doxycycline (Fig. 4-K)
|
F (2, 16) = 100.3
P < 0.0001
|
F (2, 16) = 100.3
P < 0.0001
|
F (2, 16) = 100.3
P < 0.0001
|
F (2, 16) = 100.3
P < 0.0001
|
MMP-2 - acute doxycycline (Supplementary Fig. 4-A)
|
F (2, 15) = 0.1948
P = 0.82
|
F (2, 15) = 0.1948
P = 0.82
|
F (2, 15) = 0.1948
P = 0.82
|
F (2, 15) = 0.1948
P = 0.82
|
MMP-9 - acute doxycycline (Supplementary Fig. 4-B)
|
F (2, 15) = 6.408
P < 0.001
|
F (2, 15) = 6.408
P < 0.001
|
F (2, 15) = 6.408
P < 0.001
|
F (2, 15) = 6.408
P < 0.001
|
MMP-2 chronic doxycycline (Supplementary Fig. 4-C)
|
F (2, 15) = 9.828
P < 0.01
|
F (2, 15) = 9.828
P < 0.01
|
F (2, 15) = 9.828
P < 0.01
|
F (2, 15) = 9.828
P < 0.01
|
MMP-9 chronic doxycycline (Supplementary Fig. 4-D)
|
F (2, 15) = 49.83
P < 0.0001
|
F (2, 15) = 49.83
P < 0.0001
|
F (2, 15) = 49.83
P < 0.0001
|
F (2, 15) = 49.83
P < 0.0001
|
|
RM ONE-WAY ANOVA |
RM ONE-WAY ANOVA |
RM ONE-WAY
ANOVA |
RM ONE-WAY ANOVA |
Parameter |
Treatment |
Treatment |
Treatment |
Treatment |
AIMs - acute doxycycline
(Fig. 1-A)
|
F (3, 30) = 11.07
P < 0.0001
|
F (3, 30) = 11.07
P < 0.0001
|
F (3, 30) = 11.07
P < 0.0001
|
F (3, 30) = 11.07
P < 0.0001
|
AIMs - acute COL-3
(Fig. 5-A)
|
F (1,549, 9,294) = 23.87
P < 0.001
|
F (1,549, 9,294) = 23.87
P < 0.001
|
F (1,549, 9,294) = 23.87
P < 0.001
|
F (1,549, 9,294) = 23.87
P < 0.001
|
|
TWO-WAY ANOVA |
TWO-WAY ANOVA |
TWO-WAY ANOVA |
TWO-WAY ANOVA |
Parameter |
L-DOPA Treatment |
Doxycycline
Treatment |
Doxycycline Treatment |
Interaction |
FOS-B – acute doxycycline (Fig. 2-C)
|
F (1, 16) = 54.06
P < 0.0001
|
F (1, 16) = 2.832
P = 0.1118
|
F (1, 16) = 2.832
P = 0.1118
|
F (1, 16) = 6.609
P < 0.05
|
COX-2 – acute doxycycline (Fig. 2-F)
|
F (1, 19) = 13.33
P < 0.01
|
F (1, 19) = 0.5967
P = 0.45
|
F (1, 19) = 0.5967
P = 0.45
|
F (1, 19) = 6.744
P < 0.05
|
OX-42 – acute doxycycline (Fig. 2-L)
|
F (1, 22) = 106.5
P < 0.0001
|
F (1, 22) = 14.63
P < 0.001
|
F (1, 22) = 14.63
P < 0.001
|
F (1, 22) = 7.140
P < 0.05
|
GFAP – acute doxycycline
(Fig. 2-I)
|
F (1, 22) = 98.57
P < 0.0001
|
F (1, 22) = 44.26
P < 0.0001
|
F (1, 22) = 44.26
P < 0.0001
|
F (1, 22) = 8.810
P < 0.01
|
Distance travelled in the open field - chronic doxycycline
(Supplementary table 1)
|
F (1, 21) = 21.11
P < 0.01
|
F (1, 21) = 0.153
P = 0.89
|
F (1, 21) = 0.153
P = 0.89
|
F (1, 21) = 0.07
P = 0.79
|
Time of immobility in the open field - chronic doxycycline
(Supplementary table 1)
|
F (1, 21) = 39.76
P < 0.0001
|
F (1, 21) = 2.500
P = 0.13
|
F (1, 21) = 2.500
P = 0.13
|
F (1, 21) = 1.563
P = 0.22
|
|
RM TWO-WAY ANOVA |
RM TWO-WAY ANOVA |
RM TWO-WAY
ANOVA |
RM TWO-WAY ANOVA |
Parameter |
Treatment |
Time |
Time |
Interaction |
Time course of AIMs - acute doxycycline (Fig. 1-B)
|
F (1, 10) = 15.17
P < 0.0001
|
F (9, 90) = 23.17
P = 0.003
|
F (9, 90) = 23.17
P = 0.003
|
F (9, 90) = 9.42
P < 0.0001
|
AIMs - chronic doxycycline (Fig. 4-A)
|
F (1, 30) = 492
P < 0.0001
|
F (2, 32) = 22.92
P < 0.0001
|
F (2, 32) = 22.92
P < 0.0001
|
F (2, 30) = 23.31
P < 0.0001
|
Time course of AIMs - chronic doxycycline (Fig. 4-B)
|
F (1, 10) = 746.3
P < 0.0001
|
F (9, 90) = 68.03
P < 0.0001
|
F (9, 90) = 68.03
P < 0.0001
|
F (9, 90) = 63.26
P < 0.0001
|
Time course of AIMs - acute COL-3 (Fig. 5-B)
|
F (1, 63) = 36.19
P < 0.0001
|
F (8, 63) = 13.01
P < 0.0001
|
F (8, 63) = 13.01
P < 0.0001
|
F (8, 63) = 2.974
P = 0.0069
|
|
PAIRED T-TEST |
PAIRED T-TEST |
PAIRED T-TEST |
PAIRED T-TEST |
Parameter
|
Effect
|
Effect
|
Effect
|
Effect
|
Axial, Limb and Orofacial measures AIMs – acute doxycycline
(Supplementary Fig. 2-A, -B and -C)
|
Axial:
T=1.401
P<0.05
|
Axial:
T=1.401
P<0.05
|
Limb:
T=4.422
P=0.0013
|
Orofacial:
T=2.767
P=0.0199
|
Axial, Limb and Orofacial measures AIMs – chronic doxycycline
(Supplementary Fig. 2-D, -E and -F)
|
Axial:
T=3.590
P<0.05
|
Axial:
T=3.590
P<0.05
|
Limb:
T=4.216
P=0.00012
|
Orofacial:
T=4.657
P=0.0023
|
Axial, Limb and Orofacial measures AIMs – COL-3 (Supplementary Fig.
2-G, -H and -I)
|
Axial:
T=3.738
P=0.0022
|
Axial:
T=3.738
P=0.0022
|
Limb:
T=5.259
P=0.0001
|
Orofacial:
T=2.214
P<0.05
|
b Parametric statistical analyses carried out to
calculate measures of spread from data observed in this study. ANOVA,
analysis of variance; COL-3,
CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly
known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B,
protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix
metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P
value; RM, repeated measures; ROS, reactive oxygen species; t, t value
in the student’s t-test. |
b Parametric statistical
analyses carried out to calculate measures of spread from data observed
in this study. ANOVA, analysis of variance; COL-3,
CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly
known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B,
protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix
metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P
value; RM, repeated measures; ROS, reactive oxygen species; t, t value
in the student’s t-test. |
b Parametric statistical
analyses carried out to calculate measures of spread from data observed
in this study. ANOVA, analysis of variance; COL-3,
CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly
known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B,
protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix
metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P
value; RM, repeated measures; ROS, reactive oxygen species; t, t value
in the student’s t-test. |
b Parametric statistical
analyses carried out to calculate measures of spread from data observed
in this study. ANOVA, analysis of variance; COL-3,
CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly
known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B,
protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix
metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P
value; RM, repeated measures; ROS, reactive oxygen species; t, t value
in the student’s t-test. |
b Parametric statistical
analyses carried out to calculate measures of spread from data observed
in this study. ANOVA, analysis of variance; COL-3,
CMT-3,6-demethyl-6-deoxy-4-de[dimethylamino]-tetracycline formerly
known as Incyclinide; COX-2, Cyclooxygenase-2; F, F statistic; FOS-B,
protein FOS-B; GFAP, Glial fibrillary acidic protein; MMP, Matrix
metalloproteinase; OX-42, CD11b/c equivalent protein of microglia; P, P
value; RM, repeated measures; ROS, reactive oxygen species; t, t value
in the student’s t-test. |